| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
fluvastatin is a weak inhibitor of CYP2C9.
- Weak inhibitors: ≥ 1.25-fold but < 2-fold AUC increase or ≥ 12.5% but < 50% decrease in clearance of in vivo CYP probe.
Footnotes and References
|a.||assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).|
|1.||Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. European Journal of Clinical Pharmacology 2006; 62: 291-96.[PubMed]|
|2.||Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. European Journal of Clinical Pharmacology 1988; 34: 157-63.[PubMed]|
|3.||Miners JO, Wing LMH. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. British Journal of Clinical Pharmacology 1985; 20: 482-85.[PubMed]|
|4.||Svendsen TL, Kristensen MB, Hansen JM, Skovsted L. The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. European Journal of Clinical Pharmacology 1976; 5-6: 439-41.[PubMed]|
|5.||Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clinical Pharmacology & Therapeutics 2004; 75: 89-100.[PubMed]|
|6.||Kim MJ, Nafziger AN, Kashuba ADM, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. European Journal of Clinical Pharmacology 2006; 62: 431-36.[PubMed]|
|7.||Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology & Therapeutics 2001; 69: 41-47.[PubMed]|
|8.||Krishnaiah YSR, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. British Journal of Clinical Pharmacology 1994; 37: 205-07.[PubMed]|
|9.||O'Reilly R. The stereoselective interaction of warfarin and metronidazole in man. New England Journal of Medicine 1976; 295: 354-57.[PubMed]|
|10.||Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clinical Pharmacokinetics 1997; 32: 31-36.[PubMed]|
|11.||Hansen JM, Kampmann JP, Siersbaeknielsen K, Lumholtz IB, Arroe M, Abildgaard U, Skovsted L. The effect of different sulfonamides on phenytoin metabolism in man. Acta Medica Scandinavica 1979: 106-10.[PubMed]|
|12.||Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. British Journal of Clinical Pharmacology 2003; 56: 37-44.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.